187 related articles for article (PubMed ID: 15180458)
1. Two orthogonal approaches to overcome multi-drug resistant HIV-1s: development of protease inhibitors and entry inhibitors based on CXCR4 antagonists.
Tamamura H; Fujii N
Curr Drug Targets Infect Disord; 2004 Jun; 4(2):103-10. PubMed ID: 15180458
[TBL] [Abstract][Full Text] [Related]
2. HIV co-receptors as targets for antiviral therapy.
Schols D
Curr Top Med Chem; 2004; 4(9):883-93. PubMed ID: 15134547
[TBL] [Abstract][Full Text] [Related]
3. Reduction of peptide character of HIV protease inhibitors that exhibit nanomolar potency against multidrug resistant HIV-1 strains.
Tamamura H; Koh Y; Ueda S; Sasaki Y; Yamasaki T; Aoki M; Maeda K; Watai Y; Arikuni H; Otaka A; Mitsuya H; Fujii N
J Med Chem; 2003 Apr; 46(9):1764-8. PubMed ID: 12699395
[TBL] [Abstract][Full Text] [Related]
4. Development of anti-HIV agents targeting dynamic supramolecular mechanism: entry and fusion inhibitors based on CXCR4/CCR5 antagonists and gp41-C34-remodeling peptides.
Tamamura H; Otaka A; Fujii N
Curr HIV Res; 2005 Oct; 3(4):289-301. PubMed ID: 16250877
[TBL] [Abstract][Full Text] [Related]
5. The therapeutic potential of CXCR4 antagonists in the treatment of HIV.
Fujii N; Nakashima H; Tamamura H
Expert Opin Investig Drugs; 2003 Feb; 12(2):185-95. PubMed ID: 12556213
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of HIV infection by CXCR4 and CCR5 chemokine receptor antagonists.
De Clercq E; Schols D
Antivir Chem Chemother; 2001; 12 Suppl 1():19-31. PubMed ID: 11594685
[TBL] [Abstract][Full Text] [Related]
7. HIV chemokine receptor inhibitors as novel anti-HIV drugs.
Princen K; Schols D
Cytokine Growth Factor Rev; 2005 Dec; 16(6):659-77. PubMed ID: 16005254
[TBL] [Abstract][Full Text] [Related]
8. HIV-1 entry and entry inhibitors as therapeutic agents.
Starr-Spires LD; Collman RG
Clin Lab Med; 2002 Sep; 22(3):681-701. PubMed ID: 12244592
[TBL] [Abstract][Full Text] [Related]
9. [Development of selective antagonists against an HIV second receptor].
Tamamura H
Yakugaku Zasshi; 2001 Nov; 121(11):781-92. PubMed ID: 11725546
[TBL] [Abstract][Full Text] [Related]
10. Small-molecule antagonists of CCR5 and CXCR4: a promising new class of anti-HIV-1 drugs.
Seibert C; Sakmar TP
Curr Pharm Des; 2004; 10(17):2041-62. PubMed ID: 15279544
[TBL] [Abstract][Full Text] [Related]
11. Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome.
Barbaro G; Scozzafava A; Mastrolorenzo A; Supuran CT
Curr Pharm Des; 2005; 11(14):1805-43. PubMed ID: 15892677
[TBL] [Abstract][Full Text] [Related]
12. Marked increase in anti-HIV activity, as well as inhibitory activity against HIV entry mediated by CXCR4, linked to enhancement of the binding ability of tachyplesin analogs to CXCR4.
Xu Y; Tamamura H; Arakaki R; Nakashima H; Zhang X; Fujii N; Uchiyama T; Hattori T
AIDS Res Hum Retroviruses; 1999 Mar; 15(5):419-27. PubMed ID: 10195751
[TBL] [Abstract][Full Text] [Related]
13. How to win the HIV-1 drug resistance hurdle race: running faster or jumping higher?
Garbelli A; Riva V; Crespan E; Maga G
Biochem J; 2017 Apr; 474(10):1559-1577. PubMed ID: 28446620
[TBL] [Abstract][Full Text] [Related]
14. A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140.
Tamamura H; Xu Y; Hattori T; Zhang X; Arakaki R; Kanbara K; Omagari A; Otaka A; Ibuka T; Yamamoto N; Nakashima H; Fujii N
Biochem Biophys Res Commun; 1998 Dec; 253(3):877-82. PubMed ID: 9918823
[TBL] [Abstract][Full Text] [Related]
15. Targeting CXCR4 in HIV cell-entry inhibition.
Steen A; Schwartz TW; Rosenkilde MM
Mini Rev Med Chem; 2009 Dec; 9(14):1605-21. PubMed ID: 20088780
[TBL] [Abstract][Full Text] [Related]
16. Action of anti-HIV drugs and resistance: reverse transcriptase inhibitors and protease inhibitors.
Imamichi T
Curr Pharm Des; 2004; 10(32):4039-53. PubMed ID: 15579086
[TBL] [Abstract][Full Text] [Related]
17. New advances in HIV entry inhibitors development.
Rusconi S; Scozzafava A; Mastrolorenzo A; Supuran CT
Curr Drug Targets Infect Disord; 2004 Dec; 4(4):339-55. PubMed ID: 15578975
[TBL] [Abstract][Full Text] [Related]
18. Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals.
Irlbeck DM; Amrine-Madsen H; Kitrinos KM; Labranche CC; Demarest JF
AIDS; 2008 Jul; 22(12):1425-31. PubMed ID: 18614865
[TBL] [Abstract][Full Text] [Related]
19. Agonist-induced internalization of CC chemokine receptor 5 as a mechanism to inhibit HIV replication.
Ferain T; Hoveyda H; Ooms F; Schols D; Bernard J; Fraser G
J Pharmacol Exp Ther; 2011 Jun; 337(3):655-62. PubMed ID: 21389095
[TBL] [Abstract][Full Text] [Related]
20. The open structure of a multi-drug-resistant HIV-1 protease is stabilized by crystal packing contacts.
Layten M; Hornak V; Simmerling C
J Am Chem Soc; 2006 Oct; 128(41):13360-1. PubMed ID: 17031940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
